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Abstract 
The aim of this paper was to develop and optimize the carvedilol tablets formulation using 
the full factorial design. The content of binder (PVP K30), content of disintegrant (crospovidone) 
and main compression force were used as the independent variables. Tablets were prepared by wet 
granulation. The percentage of released carvedilol from prepared formulation after 10 minutes was 
defined as the response. It has been found that formulation with the low content of binding agents 
(4.8%), high content of disintegrant (4.5%) and compression force of 50 N has the best profile of 
drug. The optimal formulation was defined based on implementation of pharmaceutical-
technological tests (testing strength, friability, disintegrating, contents of drug substance, drug 
release profiles). The stability of the optimal formulation with carvedilol was estimated using the 
aging tests. 
Keywords: carvedilol, formulation, experimental design, dissolution profile. 
 
INTRODUCTION 
 
Carvedilol is a non selective adrenergic blocking agent (Fig.1), i.e. a lipid soluble compound, which 
is practically insoluble in water and poorly absorbed from the gastrointestinal tract [1]. The slow 
absorption of carvedilol can be attributed to its poor water solubility [2, 3]. 
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Figure 1. Chemical structure of carvedilol 
 
Norepinephrine has the abilities to stimulate the nerves that control the heart muscles by binding to 
the β1- and β2-adrenergic receptors, i.e. to bind to the α1-adrenergic receptors on blood vessels, 
causing them to constrict and raise blood pressure. In these case, carvedilol has an important role to 
block binding to the β1- and β2-adrenergic receptors [4], which both slows the heart rhythm and 
reduces the force of the heart's pumping. This pharmaceutical active substance blocks the α1-
adrenergic receptors [5], which lower blood pressure. Relative to other beta blockers, carvedilol has 
minimal inverse agonist activity [6]. This suggests that carvedilol has a reduced negative 
chronotropic and inotropic effect in compared with other beta blockers. However, to date this 
theoretical benefit has not been established in clinical trials, and the current version of the 
ACC/AHA guidelines on congestive heart failure management does not give preference to 
carvedilol over other beta-blockers. It is a racemic mixture in which non-cardioselective β-
adrenergic receptor blocking activity is present in the S(-) enantiomer and selective 1-adrenergic 
receptor blocking activity is present in both R(+) and S(-) enantiomers at equal potency. At higher 
concentrations it blocks the entry of Ca
2+
 into the vascular smooth muscle. 
Experimental design is a well-known approach that commonly used in the development and 
optimization of the drug formulations [7-9]. This method enables that the desired formulation be 
achieved as fast as possible. Using this approach it is possible to analyze the influence of 
formulation factors on the selected response. Given that the types and quantities of excipients impact 
the release of the pharmaceutically active substance from the formulation, the aim of this study was 
the development and optimization of the composition of carvedilol formulation in the solid dosage 
form. The full factorial design with three variables at two levels was used to formulate the tablets 
with suitable physical and chemical properties. 
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MATERIALS AND METHODS 
 
Materials. Karvileks tablets (Zdravlje-Actavis, Leskovac, Serbia) were used for the examinations. 
One tablet contains 12.5 mg of carvedilol and other ingredients. The average mass of the tablet is 
120 mg. Dilatrend tablets were obtained as a gift sample from F. Hoffmann-La Roche, Switzerland. 
Polyvinylpyrrolidone K30 (PVP K30) was purchased from BASF, Germany and crospovidone was 
purchased from ISP Chemical, USA. All other chemicals were of analytical grade. 
Experimental design. The pharmaceutical formulations were commonly developed using the 
traditional optimization technique so-called one-variable-at-a-time. This approach requires the 
higher consumption of time, employers, chemicals and energy in compared with methodology of 
experimental design. Also, it may be difficult to find the optimal formulation since the effect 
between the process variables are not estimated. Because of these reasons, it is important to use the 
established statistical tools, such as factorial design for optimization of the content of 
pharmaceutical formulations [10-12].  
The number of experiments required for these studies is dependent on the number of independent 
variables. The response/s is/are measured for each trial and then either simple linear (Y = b0 + b1X1 + 
b2X2 + b3X3) or interactive (Y = b0 + b1X1 + b2X2 + b3X3 + b12X1X2 + b13X1X3...) or quadratic (Y = b0 + 
b1X1 +b2X2 + b3X3 + b12X1X2 + b13X1X3... + b11X1
2
), where Y is the response, b0 the intercept, b1 the 
main coefficients, bxy the interaction coefficients. Model is fitted by carrying out multiple regression 
analysis and F-statistics to identify statistically significant terms. 
The reduced equation, an equation containing only statistically significant terms, then used for 
drawing response surface plots to visualize the impact of changing variables at a glance. The 
optimum point may be identified from the plot and replicate trials may be run to verify the 
prediction of optimum response. For simplicity, it was decided to perform a three variable study at 
two experimental levels to achieve the set objectives efficiently. Design-Expert software (version 
7.1.6, Stat-Ease Inc., USA) was used for experimental design and statistical evaluation of the data. 
Development of tablets. The composition of the different formulations of Karvileks uncovered 
tablets (Zdravlje-Actavis, Leskovac, Serbia) is shown in Table 1.  
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Table 1. Composition of uncovered tablets of Karvileks 
Ingredients 
(mg per tablet) 
F1 F2 F3 F4 F5 F6 F7 F8 
Karvedilol 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 
PVP K-30 6.00 6.25 6.00 6.25 6.00 6.25 6.00 6.25 
Crospovidone 3.75 3.75 5.63 5.63 3.75 3.75 5.63 5.63 
Lactose 94.75 94.50 92.88 92.63 94.75 94.50 92.88 92.63 
Magnesium 
stearate 
2.4 2.4 2.4 2.4 2.4 2.4 2.4 2.4 
Silicium dioxide 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 
 
The matrix tablets were prepared by wet granulation method using PVP K30:water (2:1) as a binder 
solvent, lactose as a diluent, and mixture of silicium-dioxide and magnesium stearate as the glidant 
and lubricant, respectively. Crospovidone was used as a disintegrant. The quantity of lactose which 
is used as an excipience was changed in order to achieve standard specified mass of tablets. 
The ingredients were weighed accurately and passed through a 0.8 mm sieve to get uniform size 
particles and then they were mixed geometrically for 5 to 10 min. Granulation was done with a 
solution of PVP K30 in sufficient water. The granules (40 mesh) were dried in conventional hot air 
oven at 40 °C. Drying of the granules was stopped when the sample taken from the oven reached a 
loss on drying (LOD) value of 1-3%, as measured by a moisture balance at 105 °C. The dried 
granules were passed through a 1.0 mm, homogenized with crospovidone, silicium-dioxide and 
magnesium stearate and then compressed on a single punch tablet machine (Erweka EK 0, 
Germany). The tablets were round and flat with an average diameter of 7.0 ± 0.1 mm and a 
thickness of 2.6 ± 0.2 mm. 
Characterization of tablets. The prepared tablets were evaluated for mass uniformity (20 tablets) 
[13]. Hardness (10 tablets) and thickness (10 tablets) was measured by an Erweka Multicheck tester 
(Germany), and friability was determined (10 tablets) using an Erweka Friability tester TDR 100 
(Germany). Disintegration test was performed using Disintegration test apparatus by placing each 
tablet in each basket with the disc Erweka ZT301 (Germany). The process was carried out using 
water maintained at 37 °C. 
The drug content in each formulation was determined by HPLC-UV (Agilent 1100 Series, USA), 
using a Lichrosorb Si60 column (250×4,6 mm, 7µm) at 20 C, an injection volume of 20 μL and 
was detected at 280 nm.  
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The flow rate was adjusted at 2 ml/min, and the mobile phase was a mixture of 0.005 mol/l 
CH3COONa in methanol, 1,4 dioxan and acetic acid (88:10:2, v/v). The pH was adjusted to 4.0 with 
acetic acid. 20 tablets were powdered and average mass of one tablet was dissolved in mobile phase. 
The solutions were filtered through a 0.45 μm membrane filter, before analysis. 
In vitro drug release studies. The in vitro drug release studies were conducted using the USP 28 
type II (10) (paddle) dissolution apparatus (Erweka). 1000 ml of citrate buffer (pH 4.5) was used as 
medium. The study was conducted at 37 ± 0.5 °C and at paddle rotation of 75 rpm. Samples of 5 ml 
were collected at predetermined time intervals and replaced with fresh citrate buffer. The samples 
were filtered and diluted and the drug content in the samples was estimated at 285 nm using an 
Agilent 8453 UV–VIS spectrophotometer. Cumulative percentage drug release was calculated using 
an equation obtained from a standard curve. Mathematical models, zero-order, first-order and 
Korsmayer-Peppas were applied to analyze the release mechanism and pattern [14]. 
Similarity factor (f2) analysis. In vitro release profile of carvedilol from selected Karvileks tablet 
formulations and the marketed sustained release tablets were performed under similar conditions. 
The similarity factor between the two formulations was determined using the data obtained from the 
drug release study. The data was analyzed by the equation 1: 
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where are N - number of time points, Ri and Ti - dissolution of reference and test products at time 
"i". If f2 is greater than 50 it is considered that two formulations share similar drug release behaviors. 
Stability studies. Optimized formulation tablets were packed in suitable primary packaging and 
then kept at 45 C and 75% relative humidity (RH) for 6 months in order to perform the accelerated 
stability test. At the end of 3 months, the tablet properties including hardness, friability and 
disintegration time as well as drug content and dissolution were evaluated. 
 
RESULTS AND DISCUSSION 
 
Interpretation of the effects  
The estimated effects are usually graphically or/and statistically interpreted, to determine their 
significance. In our opinion, combining a graphical with a statistical evaluation can be 
recommended. Graphical methods consist in drawing normal probability or half-normal probability 
plots. They can be constructed manually by the analyst or obtained by use of statistical software.  
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Both graphs plot the (absolute) factor effects as a function of values derived from a normal 
distribution. The non-significant effects are found on a straight line through zero line where as the 
significant effects deviate from this line. Half normal probability plot is shown in Figure 2. 
 
 
Figure 2. Half-normal probability plots for the seven effects on the response carvedilol dissolved 
 
Building the model 
After executing the experiments and determining the responses, the polynomial or factorial models 
describing the relationships between the responses and the considered factors can be built. Models 
usually includes an intercept, the main effect terms, the interaction terms, and quadratic terms. 
Occasionally, not all terms are included in the model and/or the non-significant terms are excluded, 
for instance, using the backward elimination regression procedure. Interactive statistical first-order 
complete model was generated to evaluate carvedilol disolved after 10 min. Final equation was 
given in terms of coded factors: 
3213221321 94.116.357.102.712.378.420.7710 XXXXXXXXXXdissolvedCarvedilol Q   
The main effects (X1, X2 and X3) represent the average result of changing one factor at a time from 
its low to high value. The interactions (X1X2, X2X3 and X1X2X3) show how the carvedilol disolved 
value changes when two or more factors are simultaneosly changed. 
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The carvedilol disolved values for the eight formulations show a wide variation, i.e. the response 
ranges from a minimum of 59.24 to a maximum of 93.20% in 10 min. The data clearly indicates that 
the carvedilol disolved is strongly dependant of the factors. 
It may be concluded that the low levels of X1 (binder concentration) and X3 (main compression 
force) and high level of X2 (desintegrant concetration) appear to favour the preparation of carvedilol 
tablets with desired dissolution after 10 min. 
 
Evaluation of the model 
After building the model, it can be interpreted graphically and/or statistically. Graphically, the 
model can be visualized by drawing 2D contour plots or 3D response-surface plots. A 2D contour 
plot shows the isoresponse lines as a function of the levels of two factors, while a 3D response-
surface plot represents the response, on a third dimension, as a function of the levels of two factors. 
Graphical representation of the model built for the response carvedilol dissolved at hardness of 50 
and 70 N as: (a) 2D contour plot, and (b) 3D response-surface plot are shown in Figures 3 and 4. 
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Figure 3. Graphical representation of the model built for the response carvedilol dissolved after 10 min at 
hardness 50 N as: (a) 2D contour plot, and (b) 3D response-surface plot 
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Figure 4. Graphical representation of the model built for the response carvedilol dissolved after 10 min at 
hardness 70 N as: (a) 2D contour plot, and (b) 3D response-surface plot 
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The ANOVA results of regression analysis for the simple model are depicted in Table 2. The 
obtained results showed that the main compression force (X3) was the most significant carvedilol 
release factor: the lower hardness of tablets give better dissolution profile. Factor binding 
concentration PVP K30 (X1) has less influence on dissolution profile of carvedilol, while factor 
disintegrant concentration crospovidone (X2) had no significant influence in this study. 
 
Table 2. ANOVA test of the experimental design results 
factor df sum of squares mean square 
Model 6 784.74 130.79 
X1 1 182.60 182.60 
X2 1 78.00 78.00 
X3 1 394.24 394.24 
X1 X2 1 19.66 19.66 
X2 X3 1 80.14 80.14 
X1 X2X3 1 30.11 30.11 
Residual  1 0.48 0.48 
 
Determination of the optimal formulation 
In an optimization context, the model is most frequently used to predict the optimum. Often the 
optimum is selected from the graphical representation of the model. The overlay plot provided by 
the Design expert software showed an acceptable region that met the requirement of the response 
(Fig. 5). 
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Figure 5. The overlay plot for carvedilol dissolved after 10 min at hardness of 50 N (a),  
and at hardness of 70N (b) 
 
Evaluation of tablets 
The uncovered tablets of Karvileks were prepared by wet granulation technique using lactose and 
PVP K30. The silica-dioxide, magnesium stearate and crospovidone were used in the phase of 
homogenization. The results of the physico-chemical characterization are shown in Table 3. 
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Тable 3. Physico-chemical characterization of Karvileks tablets 
Formulation 
Uniformity of 
weight (mg) 
Hardness 
(N) 
Friability 
(%) 
Disintegration 
time (min) 
Drug content 
(mg) 
F1 122.0 50 0.1 3.8 12.71 
F2 120.3 50 0.13 4.5 12.48 
F3 121.9 50 0.07 3.5 12.53 
F4 121.4 50 0.1 3.8 12.58 
F5 120.9 70 0.05 7.5 12.68 
F6 120.8 70 0.08 9.5 12.39 
F7 120.7 70 0.07 7.0 12.42 
F8 120.9 70 0.03 8.1 12.55 
 
The weight of the tablet varied between 120.3 mg to 122.0 mg for different formulations with low 
standard deviation values, indicating uniformity of weight. The variation in weight was within the 
range of ±7.5% complying with pharmacopoeial specifications. The hardness for different 
formulations was found to be between 50 to 70 N indicating satisfactory mechanical strength. The 
friability was below 1% for all the formulations, which is an indication of good mechanical 
resistance of the tablet. 
The drug content varied between 12.39 to 12.71 mg in different formulations with low coefficient of 
variation (C.V.< 1.0%), indicating content uniformity in the prepared batches. The disintegration 
time was found to be in the range of 3.7 to 12.5 min for all the formulations. 
 
In vitro dissolution studies 
The pharmacokinetic parameters of carvedilol were used to calculate a theoretical drug release 
profile for an eight dosage form
 
[15]. The percent of carvedilol dissolved was determined by UV-
VIS spectrophotometric method at 285 nm, after 10, 20, 30 i 60 min. The in-vitro drug release 
profiles of carvedilol for all the formulations and the marketed product are shown in Figure 6. 
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Figure 6. Dissolution properties of carvedilol 
 
The experimental design 2
3
 was applied with following independent variables: binder concentration 
PVP K30 (X1), disintegrant concentration crospovidone (X2), resistance to crushing (X3), while 
percent of carvedilol dissolved (Y1) after 10 min was used as dependent variable (Table 4). 
 
Table 4. Experimental design table 
Exp. X0 X1 X2 X3 
X1 
Binder 
concentration 
(%) 
X2 
Disintegrant 
concentration 
(%) 
X3 
Hardness 
(N) 
Y1 
% of carvedilol 
dissolved 
1 + - - - 4.8 3.0 50 92.30 
2 + + - - 5.0 3.0 50 76.22 
3 + - + - 4.8 4.5 50 85.20 
4 + + + - 5.0 4.5 50 83.15 
5 + - - + 4.8 3.0 70 68.54 
6 + + - + 5.0 3.0 70 59.24 
7 + - + + 4.8 4.5 70 81.86 
8 + + + + 5.0 4.5 70 71.07 
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Drug release profiles of formulations F1-F4, (resistance to crushing of 50 N), showed a release of 
92.30, 76.22, 85.20 and 83.15% in 10 min, respectively (Table 5).  
 
Table 5. Drug release profiles of formulations F1-F8 and Dilatrend tablets 
t,  
min 
exp. 1 exp. 2 exp. 3 exp. 4 exp. 5 exp. 6 exp. 7 exp. 8 
Dilatrend 
tablets 
0 0 0 0 0 0 0 0 0 0 
10 92.30 76.22 85.20 83.15 68.54 59.24 81.86 71.07 89.78 
20 96.61 86.65 91.92 91.57 93.49 71.27 95.64 89.93 93.04 
30 99.29 94.66 98.54 96.17 97.28 81.54 100.30 94.77 96.90 
60 104.73 97.76 100.94 103.65 103.24 87.21 104.88 99.04 103.20 
 
It is expected that the developed formulation should have the following theoretical drug release 
profile over 80% after 10 min [16]. Formulations F1, F3 and F4 met the needed theoretical drug 
release profile and from these reason, it was considered the suitable formulations among all the four 
formulations of this series.  
Drug release profiles of formulations F5-F8 (resistance to crushing of 70 N) are shown in Table 5. 
The percentage of drug released from formulations F5-F8 was 76.12, 58.42, 86.64 and 79.70%, 
respectively, in 10 min. However, formulations F5, F6 and F8 failed to meet the required theoretical 
drug release profile. Formulation F7 met the desired theoretical drug release profile. Therefore, it 
was considered the best formulation among all the four formulations of this series. 
However, formulation F3 met the theoretical drug release profile. Also, taking into consideration 
results for friability, desintegration and drug content, this formulation complied with all specified 
physical and chemical properties. Therefore, formulation F3 was considered the most suitable 
formulation among all the eight formulations.  
 
Drug release kinetics  
The data obtained from in vitro dissolution studies were fitted in different models zero order, first 
order and Korsemeyer‘s equation (Table 6). In order to confirm the exact mechanism of drug release 
from these tablets, the data were fitted in accordance with Korsemeyer‘s equation [17]. Regression 
analysis was performed and regression values r
2
 were 0.888 to 0.998 for different formulations.  
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Table 6. Kinetics of in vitro carvedilol release from Karvileks tablets 
Formulation 
Zero order First order 
Korsemeyer 
model 
k0 
(mg/min) 
r
2 
k1 
1/min 
r
2 
n r
2 
F1 0.235 0.957 0.119 0.968 0.079 0.998 
F2 0.387 0.756 0.046 0.935 0.145 0.917 
F3 0.289 0.779 0.115 0.928 0.098 0.950 
F4 0.379 0.910 0.074 0.998 0.122 0.998 
F5 0.457 0.717 0.108 0.986 0.168 0.888 
F6 0.525 0.804 0.023 0.903 0.228 0.941 
F7 0.326 0.819 0.112 1.000 0.103 0.968 
F8 0.341 0.784 0.060 0.997 0.121 0.954 
 
Similarity factor analysis between the formulation F3 of Karvileks and marketed product for the 
drug release showed the f2 factor of 76.75, which is greater than 50. This value indicate that the 
release of the drug from the prepared tablets is similar to the marketed tablet. 
 
Stability studies 
Physical properties of the optimized formulation (F3) after keeping it in accelerated stability 
conditions (45 °C and 75% RH) are illustrated in Table 7. Hardness of tablets was in the range of 
48.93 – 51.32 N, which was considered as acceptable for tablet formulations. After exposure to the 
stability testing conditions for three months, despite the fact that the disintegration time and 
friability of tablets were in the ranges of 3.50 – 4.10 min and 0.07 – 0.14%, respectively, the tablets 
were still within the limits defined for these variables. Drug content of tablets was ranged from 
100.10 to 99.20% at the end of stability studies. 
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Table 7. Physicochemical characteristics of the optimized formulation (F3) 
after accelerated stability studies (45 °C and 75% RH) 
Dependant variable 
Time (months) 
0 3
 
6 
Hardness (N) 48.93 ± 3.17 51.04 ± 4.39 51.32 ± 3.41 
Disintegration time (min) 3.50 ± 0.20 4.00 ± 0.10 4.10 ± 0.20 
Friability (%) 0.07 0.12 0.14 
Drug content (%) 100.10 ± 1.76 99.80 ± 1.23 99.20 ± 1.65 
Q10 85.20 ± 2.84 84.90 ± 1.98 83.02 ± 2.76 
Q60 100.94 ± 0.57 97.62 ± 2.43 99.89 ± 1.54 
 
The results of dissolution studies for tablets after stability experiments are represented in Table 7. It 
was shown that the data were very close to the freshly prepared tablets and more than 80% of 
carvedilol got dissolved from all tablets in the first 10 min of the test (Q10). As mentioned above, the 
disintegration time of tablets exposed to the stability testing conditions was increased compared to 
fresh tablets. The slight decrease of the drug dissolved from the tablets in the first 10 min could be 
attributed to the finding. In conclusion, the optimized formulation F3 could be considered stable 
even after 6 months of being kept under accelerated stability conditions. 
 
CONCLUSION 
This study demonstrates the use of factorial design for the development and optimization of 
carvedilol tablet formulation. This statistical technique allows scientists to examine more than one 
independent variable at a time. The desirable goals can be obtained by systematic formulation 
approach in shortest possible time. Obtained results showed that the most significant factor for 
dissolution profile of carvedilol from Karvileks tablets (Zdravlje-Actavis, Serbia) was the main 
compression forse. Considering the individual response evaluation, the most suitable carvedilol 
tablet formulation should present in its component PVP K30 - low level, disintegrant - high level, 
and main compression force-low level. 
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Izvod 
Primenom metodologije punog faktorijalnog dizajna u radu je izvršen razvoj i optimizacija 
formulacije tableta na bazi karvedilola. Sadrţaj vezivnog sredstva i sredstva za raspadanje, odnosno 
sila komprimovanja tokom izvoĊenja eksperimenta definisane su kao nezavisno promenljive 
veliĉine. Procenat oslodoĊenog karvedilola iz pripremljenih formulacija nakon 10 min izabran je 
kao zavisno promenljiva veliĉina. Na osnovu dobijenih rezultata utvrĊeno je da formulacija sa 
niskim sadrţajem sredstva za vezivanje (4,8%), visokim sadrţajem sredstva za raspadanje (4,5%) i 
silom komprimovanja od 50 N ima najbolji profil oslobaĊanja lekovite supstance. MeĊutim, 
optimalna formulacija sa najboljim fiziĉkim svojstvima odabrana je nakon sprovoĊenja 
farmaceutsko-tehnoloških testova (ispitivanje ĉvrstine, friabilnosti, raspadljivosti, sadrţaja lekovite 
supstance, profila oslobaĊanja lekovite supstance). Primenom testova starenja odreĊena je stabilnost 
optimalne formulacije karvedilola.  
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